Lisinopril and Pulse abnormal - a phase IV clinical study of FDA data

Summary:

Pulse abnormal is reported as a side effect among people who take Lisinopril (lisinopril), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have Pain.

The phase IV clinical study analyzes which people have Pulse abnormal when taking Lisinopril. It is created by eHealthMe based on reports of 343,814 people who have side effects when taking Lisinopril from the FDA, and is updated regularly.

What is Lisinopril?

Lisinopril has active ingredients of lisinopril. It is often used in high blood pressure. eHealthMe is studying from 358,654 Lisinopril users. Check the latest studies of Lisinopril.

What is Pulse abnormal?

Pulse abnormal is found to be associated with 433 drugs and 490 conditions by eHealthMe. Check the latest studies of Pulse abnormal.

On Jul, 27, 2026

343,814 people reported to have side effects when taking Lisinopril.
Among them, 62 people (0.02%) have Pulse abnormal.

Among these 62 people:

How long have people been on Lisinopril when they have Pulse abnormal? *

What is the gender of people who have Pulse abnormal when taking Lisinopril? *

female: 57.38 %
male: 42.62 %

What is the age of people who have Pulse abnormal when taking Lisinopril? *

What are other drugs people take besides Lisinopril? *

What are other side effects people have besides Pulse abnormal? *

Dyspnea (difficult or laboured breathing): 19 people, 30.65%
Chest Pain: 16 people, 25.81%
Hypotension (abnormally low blood pressure): 15 people, 24.19%
Hyperhidrosis (abnormally increased sweating): 10 people, 16.13%
Feeling Cold: 10 people, 16.13%
Fatigue (feeling of tiredness): 10 people, 16.13%
Skin - Clammy: 9 people, 14.52%
Stress And Anxiety: 8 people, 12.90%
Pain: 8 people, 12.90%
Nausea (feeling of having an urge to vomit): 7 people, 11.29%

What are the existing conditions these people have? *

High Blood Cholesterol: 6 people, 9.68%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 9.68%
Pain: 6 people, 9.68%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 8.06%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 6.45%
Multiple Myeloma (cancer of the plasma cells): 3 people, 4.84%
Stress And Anxiety: 3 people, 4.84%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 4.84%
Atherosclerosis (disorder of the arteries): 3 people, 4.84%
Hypovitaminosis (any of several diseases caused by deficiency of one or more vitamins): 2 people, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Lisinopril and have Pulse abnormal?

- Check whether Pulse abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lisinopril:

Lisinopril (358,654 reports)

Pulse abnormal treatments and more:

Pulse abnormal (2,933 reports)

Browse all side effects of Lisinopril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulse abnormal:

Pulse abnormal (433 drugs)

Browse all the conditions that are associated with Pulse abnormal:

Pulse abnormal (490 conditions)

Related publications that referenced our studies

Dobrosavljevi? Vukojevi? D, Stojkovi? Filipovi? J, Sjerobabin M, Vukovi? J, Vesi? S, "Lisinopril-induced pemphigus foliaceus in a patient with diabetes mellitus and Kaposi-Juliusberg varicelliform eruption", Serbian Journal of Dermatology and Venerology, 2012 Dec .
Dobrosavljevi? Vukojevi? D, Stojkovi? Filipovi? J, Sjerobabin M, Vukovi? J, Vesi? S, "Lisinopril-induced pemphigus foliaceus in a patient with diabetes mellitus and Kaposi-Juliusberg varicelliform eruption", Serbian Journal of Dermatology and Venerology, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on lisinopril (the active ingredients of Lisinopril) and Lisinopril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.